Subtype
Esophageal Squamous Cell Carcinoma
CI-CAN-00002629ESCCExplore in graph →
212 active trials3 approved drugs7 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00002629ESCCExplore in graph →
Clinical trials
555 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (35)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02272699 | Neoadjuvant Treatment of Nimotuzumab With Chemotherapy or Radiotherapy in Resectable Esophageal Squamous Cell Carcinoma | withdrawn | Phase 2 / Phase 3 | 0 | Peking UniversityOTHER | 1 | Mar 18, 2021 | clinicaltrials |
| NCT04797507 | SHR-1210 in Combination With Anlotinib in Patients With Advanced or Metastatic Esophageal Squamous Cell Cancer | unknown | Phase 2 | 33 | Peking Union Medical College HospitalOTHER | 0 | Mar 15, 2021 | clinicaltrials |
| NCT04084158 | A Study of Toripalimab Combined With Concurrent Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma. | suspended | Phase 2 | 100 | Zhejiang Cancer HospitalOTHER | 1 | Feb 23, 2021 | clinicaltrials |
| NCT04767295 | A Study of Camrelizumab Combined With Chemotherapy as Neoadjuvant Therapy in Adcanced Esophageal Squamous Cell Carcinoma (ESCC) | unknown | Phase 2 | 28 | Hunan Cancer HospitalOTHER | 1 | Feb 23, 2021 | clinicaltrials |
| NCT00064259 | A Phase I/II Study of Oblimersen Plus Cisplatin and Fluorouracil in Gastric & Esophageal Junction Cancer | terminated | Phase 1 / Phase 2 | 15 | National Cancer Institute (NCI)NIH | 1 | Feb 17, 2021 | clinicaltrials |
| NCT03116152 | Study of IBI308 With Advanced/Metastatic Esophageal Squamous Cell Carcinoma After Failure of First-line Treatment | completed | Phase 2 | 190 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Feb 3, 2021 | clinicaltrials |
| NCT04225364 | Efficacy of Neoadjuvant PD-1 Blockade Plus Chemotherapy for Esophageal Squamous Cell Carcinoma | completed | Phase 2 | 56 | Guangzhou Institute of Respiratory DiseaseOTHER | 1 | Feb 2, 2021 | clinicaltrials |
| NCT03377400 | Definitive CCRT Combined With Durvalumab and Tremelimumab for Inoperable Esophageal Cancer | unknown | Phase 2 | 40 | Samsung Medical CenterOTHER | 1 | Dec 17, 2020 | clinicaltrials |
| NCT03987815 | Neoadjuvant Nivolumab for Operable Esophageal Carcinoma | unknown | Phase 2 | 20 | Samsung Medical CenterOTHER | 1 | Dec 17, 2020 | clinicaltrials |
| NCT04644250 | Combination of Toripalimab and Neoadjuvant Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma | unknown | Phase 2 | 32 | Wei RenOTHER | 1 | Nov 25, 2020 | clinicaltrials |
| NCT04602013 | Sintilimab Injection Combined With Concurrent CCRT in Locally Advanced Esophageal Squamous Cell Carcinoma | unknown | Phase 2 | 53 | Sichuan Cancer Hospital and Research InstituteOTHER | 1 | Oct 26, 2020 | clinicaltrials |
| NCT04481100 | CCRT With Itraconazole in Locally Advanced Squamous Esophageal Cancer | unknown | Phase 2 | 38 | Hangzhou Cancer HospitalOTHER | 1 | Oct 14, 2020 | clinicaltrials |
| NCT02606916 | Radiotherapy Combined With S-1/DDP for Elderly Esophageal Squamous Cell Cancer. | completed | Phase 2 | 42 | Sun Yat-sen UniversityOTHER | 1 | Sep 4, 2020 | clinicaltrials |
| NCT03187314 | Combination of Radiation Therapy and Anti-PD-1 Antibody SHR-1210 in Treating Patients With Esophageal Cancer | completed | Phase 2 | 25 | Hangzhou Cancer HospitalOTHER | 1 | Aug 17, 2020 | clinicaltrials |
| NCT04503967 | Efficacy and Safety of Anlotinib Hydrochloride Combined With Nivolumab in the Treatment of Gastric and Esophageal Cancer(OASIS) | unknown | Phase 2 | 48 | Shanghai Zhongshan HospitalOTHER | 0 | Aug 7, 2020 | clinicaltrials |
| NCT04437212 | Neoadjuvant Chemoradiotherapy Combined With Perioperative Toripalimab in Locally Advanced Esophageal Cancer | unknown | Phase 2 | 20 | RenJi HospitalOTHER | 1 | Jun 26, 2020 | clinicaltrials |
| NCT02017600 | A Phase II Trial of Induction Chemotherapy With ND-420, Cisplatin and Fluorouracil Followed by Surgery in the Treatment of Patients With Localized Squamous Cell Carcinoma of the Esophagus | terminated | Phase 2 | 48 | Nang Kuang Pharmaceutical Co., Ltd.INDUSTRY | 1 | May 20, 2020 | clinicaltrials |
| NCT02123381 | Changes in Tumor Tissue and Serum Biomarkers Before and After Cetuximab Combined With Preoperative Radiotherapy in Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma | unknown | Phase 2 | 100 | Sichuan Cancer Hospital and Research InstituteOTHER | 1 | Mar 17, 2020 | clinicaltrials |
| NCT03603756 | SHR-1210 in Combination With Apatinib and Chemotherapy in Patients With Advanced Esophageal Squamous Cell Cancer | unknown | Phase 2 | 45 | Chinese Academy of Medical SciencesOTHER | 1 | Feb 11, 2020 | clinicaltrials |
| NCT03913182 | Apatinib in the Treatment of Recurrence or Metastasis of Esophageal Cancer | unknown | Phase 2 | 39 | Shanghai Chest HospitalOTHER | 1 | Feb 5, 2020 | clinicaltrials |
| NCT04229849 | Anrotenib Plus Toripalimab Versus Toripalimab in Patients With Advanced Esophageal Squamous Cell Carcinoma | unknown | Phase 2 | 164 | Henan Cancer HospitalOTHER_GOV | 0 | Jan 18, 2020 | clinicaltrials |
| NCT04006041 | Combination of Toripalimab and Neoadjuvant Chemoradiotherapy in Esophageal Cancer | unknown | Phase 2 | 44 | Jianhua FuOTHER | 1 | Dec 26, 2019 | clinicaltrials |
| NCT04115618 | SIB in Upper Thoracic Esophageal Squamous Cell Carcinoma | unknown | Phase 2 | 65 | Fudan UniversityOTHER | 1 | Oct 4, 2019 | clinicaltrials |
| NCT04054518 | Durvalumab as Maintenance Following Chemoradiation for Unresectable Esophageal Squamous Cell Carcinoma(DESC) | unknown | Phase 2 | 22 | Tiago BiachiOTHER | 1 | Aug 13, 2019 | clinicaltrials |
| NCT03185988 | Anti-HER2 Therapy in Patients of HER2 Positive Metastatic Carcinoma of Digestive System | unknown | Phase 2 | 100 | Shen LinOTHER | 1 | Jul 19, 2019 | clinicaltrials |
| NCT03940976 | Afatinib in Previously Treated ESCC With EGFR Overexpression or EGFR Amplification (ESCC-A01) | unknown | Phase 2 | 40 | Peking UniversityOTHER | 1 | Jun 11, 2019 | clinicaltrials |
| NCT02649361 | Study of Anlotinib in Patients With Esophageal Squamous Cell Carcinoma (ALTER1102) | completed | Phase 2 | 164 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Jun 5, 2019 | clinicaltrials |
| NCT03927495 | KN046 in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma | unknown | Phase 2 | 100 | Shanghai Chest HospitalOTHER | 1 | May 29, 2019 | clinicaltrials |
| NCT03584308 | Efficacy of VIUSID® Plus GLIZIGEN® in Patients With Papilloma Virus Esophageal | completed | Phase 2 | 110 | Catalysis SLINDUSTRY | 1 | May 22, 2019 | clinicaltrials |
| NCT01248299 | Benefit of Chemotherapy Over Best Supportive Care in Metastatic and Squamous Cell-type Esophageal Cancer.(E-DIS) | terminated | Phase 2 | 105 | Centre Oscar LambretOTHER | 1 | May 16, 2019 | clinicaltrials |
| NCT02812641 | Neoadjuvant CCRT With/Without Bevacizumab for Locally Advanced ESCC | unknown | Phase 2 | 50 | National Taiwan University HospitalOTHER | 1 | Mar 11, 2019 | clinicaltrials |
| NCT03857763 | A Prospective Study of Apatinib Plus Concurrent Neoadjuvant Chemoradiotherapy in Patients With Esophageal Squamous Cell Carcinoma | unknown | Phase 2 | 40 | Hebei Medical University Fourth HospitalOTHER | 0 | Feb 28, 2019 | clinicaltrials |
| NCT01831531 | Study of S-1 in Combination With Radiotherapy in Esophageal Cancer | completed | Phase 2 | 105 | Fudan UniversityOTHER | 1 | Feb 15, 2019 | clinicaltrials |
| NCT03833466 | Metformin in Combined With Cisplatin Plus Paclitaxel With Advanced Esophageal Squamous Cell Carcinoma (ECMTPneo)(ECMTPneo) | unknown | Phase 2 | 15 | Peking UniversityOTHER | 1 | Feb 15, 2019 | clinicaltrials |
| NCT02353936 | A Phase II Trial of Afatinib in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of Esophagus | unknown | Phase 2 | 30 | Yonsei UniversityOTHER | 1 | Feb 11, 2019 | clinicaltrials |
| NCT03817567 | Safety and Efficacy of SCT200 in Patients With Advanced Esophageal Squamous Cell Carcinoma | unknown | Phase 1 / Phase 2 | 50 | Sinocelltech Ltd.INDUSTRY | 1 | Jan 25, 2019 | clinicaltrials |
| NCT03817658 | A Phase II Study of SHR-1210 vs Placebo as Consolidation Chemotherapy After Radical Concurrent Chemoradiotherapy in Locally Advanced ESCC | unknown | Phase 2 | 725 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 1 | Jan 25, 2019 | clinicaltrials |
| NCT03732508 | SHR-1316 in Combination With Chemotherapy in Patients With Esophageal Squamous Cell Cancer | unknown | Phase 2 | 30 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Nov 6, 2018 | clinicaltrials |
| NCT03223662 | Metabolomic and BH3 Profiling of Esophageal Cancers: Identification of Novel Assessment Methods of Treatment Response for Precision Therapy | terminated | Phase 2 | 2 | National Cancer Institute (NCI)NIH | 1 | Oct 30, 2018 | clinicaltrials |
| NCT03585673 | Docetaxel-polymeric Micelles(PM) and Oxaliplatin for Esophageal Carcinoma(DOSE) | unknown | Phase 2 | 38 | Sung Yong OhOTHER | 1 | Jul 17, 2018 | clinicaltrials |
| NCT01612546 | Pilot Trial of CRLX101 in Treatment of Patients With Advanced or Metastatic Stomach, Gastroesophageal, or Esophageal Cancer That Cannot be Removed by Surgery | completed | Phase 2 | 10 | City of Hope Medical CenterOTHER | 1 | Feb 1, 2018 | clinicaltrials |
| NCT03307941 | Assessment of Metabolic & Path Response w/ RCT & ImT Before Surgery in Locally Advanced Esoph and Gastro-esoph Jction CA(ARTEMIS-Eso) | withdrawn | Phase 1 / Phase 2 | 0 | Jules Bordet InstituteOTHER | 1 | Dec 19, 2017 | clinicaltrials |
| NCT01178944 | Pralatrexate and Oxaliplatin in Treating Patients With Unresectable or Metastatic Esophageal, Stomach, or Gastroesophageal Junction Cancer | completed | Phase 2 | 35 | Roswell Park Cancer InstituteOTHER | 1 | Dec 13, 2017 | clinicaltrials |
| NCT02384811 | Phase II Study of Extensive Clinical Target Volumes in Postoperative Radiotherapy for Esophageal Squamous Cell Carcinoma | unknown | Phase 2 | 70 | Fudan UniversityOTHER | 1 | Sep 7, 2017 | clinicaltrials |
| NCT03224221 | Apatinib Combined With Chemotherapy for Esophageal Squamous Cell Cancer After the Failure of Standard Treatment | unknown | Phase 2 | 189 | The First Affiliated Hospital of Anhui Medical UniversityOTHER | 1 | Jul 21, 2017 | clinicaltrials |
| NCT01807546 | Oral Rigosertib for Squamous Cell Carcinoma | completed | Phase 2 | 64 | Traws Pharma, Inc.INDUSTRY | 1 | Jun 26, 2017 | clinicaltrials |
| NCT02913066 | S-1 IMRT Versus S-1 and Cisplatin Concurrent IMRT in Inoperable Esophageal Squamous Cell Carcinoma | unknown | Phase 2 | 88 | Mianyang Central HospitalOTHER | 1 | Jun 16, 2017 | clinicaltrials |
| NCT00816634 | Efficacy Comparison Study of Combination Regimens to Treat Advanced Esophageal Squamous Cell Carcinoma(XP versus XT) | unknown | Phase 2 | 94 | Samsung Medical CenterOTHER | 1 | May 1, 2017 | clinicaltrials |
| NCT01608022 | A Phase II Trial of PF-00299804 in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of Esophagus | completed | Phase 2 | 48 | Yonsei UniversityOTHER | 1 | Sep 7, 2016 | clinicaltrials |
| NCT01129206 | Pralatrexate and Docetaxel in Treating Patients With Stage IV Esophageal or Gastroesophageal Cancer Who Have Failed Platinum-Based Therapy | completed | Phase 2 | 6 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Jun 1, 2016 | clinicaltrials |
Data updated 23 days agoSource updated Mar 18, 2021source: clinicaltrials